dumbcritic

dumbcritic's Recent CancerCompass Activity

• dumbcritic has replied to a post on the message board

  Vidac Pharma has announced the inclusion of the first patient in a placebo controlled PhII trial for early forms of CTCL treated with its first-in-class drug VDA-1102. This disrupts the binding of HK2 from VDAC. 

  February 20 at 10:41 PM view post

• dumbcritic has replied to a post on the message board

  A new company, who will be in the clinic soon https://penrosetherapeutx.com/science-and-pipeline/

  February 19 at 2:40 AM view post

• dumbcritic has replied to a post on the message board

  Early human data in patients with refractory CRC [1] and more info on the drug itself [2]. Refs: 1 https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e16027 2 http://www.metimedi.com/science/cancermetabolism.php

  July 15 at 11:29 PM view post

• dumbcritic has replied to a post on the message board

  Clinical data on IM156 [1], Devimistat [2], and preclinical for IACS-010759 [3]. Refs: 1 https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3590 2 https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4635 3 https://jitc.bmj.com/content/8/1/e000289

  June 30 at 11:16 PM view post

• dumbcritic has replied to a post on the message board

  DRP-104 https://www.dracenpharma.com/wp-content/uploads/2020/06/AACR-2020_5607.pdf RGX-202 https://www.businesswire.com/news/home/20200529005040/en/RGENIX-Shows-Clinical-Activity-Agent-RGX-202-Patients SM-88 https://www.businesswire.com/news/home/20200622005031/en/TYME-Presents-New-Preclinical-Data-Supporting-SM-88

  June 22 at 11:17 PM view post

• dumbcritic has replied to a post on the message board

  There are some unpublished data in humans (n=2) showing this. If you skip to the 43:39 minute mark in this video you can see it [1]. The FDA has not only granted accelerated approval to certain anti-cancer drugs based on objective response rates [2], but also approved them on that basis. Refs: 1 https://videocast.nih.gov/watch=13394 2 https://en.wikipedia.org/wiki/Response_evaluation_criteria_in_solid_...

  June 22 at 12:51 AM view post

• dumbcritic has created a new message board discussion

  Many of the mutations in the DNA of a cancer cell will lead to changes in the proteins expressed on it's surface and these can be recognised by the immune system as 'foreign.' As a consequence, such specific neoantigens can be targeted by different types of immunotherapies, which will attack cancer cells, but shouldn't have an effect on any healthy cells. In this trial* they take blood from patients and determine ...

  April 06 at 12:16 AM view discussion

• dumbcritic has replied to a post on the message board

  No, it isn't https://rationalwiki.org/wiki/Cancer_Tutor

  January 19, 2020 view post

• dumbcritic has replied to a post on the message board

  I've just come across this paper from back in March. A Specific Ketogenic Diet (SKD), Ozone Therapy, HBOT, and herbal supplements were used. "Results: After Phase (1) of this research on 54 patients the average percentage decrease in the tumors was 58% and after Phase (2) on 31 remaining cancer patients the average percentage decrease in the tumors was 98.8%.'' https://researchopenworld.com/the-positive-effec...

  October 31, 2019 view post

• dumbcritic has replied to a post on the message board

  RP2 moves forward https://www.globenewswire.com/news-release/2019/10/24/1934915/0/en/Replimune-Announces-First-Patient-Enrolled-in-Phase-1-Clinical-Trial-of-RP2-Alone-and-in-Combination-with-Opdivo-in-Advanced-Cancer-Patients.html

  October 24, 2019 view post